A novel monoclonal antibody with improved FcγR blocking ability demonstrated non-inferior efficacy compared to IVIG in cynomolgus monkey ITP model at considerably lower dose

Intravenous immunoglobulin (IVIG) is a well-established treatment for various autoimmune and inflammatory diseases. However, the standard dose prescribed for autoimmune diseases, including immune thrombocytopenic purpura (ITP), is 2 g/kg, which is markedly high and leads to a high treatment burden....

Descripción completa

Detalles Bibliográficos
Autores principales: Nakajima-Kato, Yuko, Komai, Masato, Yoshida, Tadashi, Kanai, Akiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Autoimmunity/Autoimmune Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9993454/
https://www.ncbi.nlm.nih.gov/pubmed/36480334
http://dx.doi.org/10.1093/cei/uxac112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9993454/
https://www.ncbi.nlm.nih.gov/pubmed/36480334
http://dx.doi.org/10.1093/cei/uxac112

Ejemplares similares